

JÃ©rÃ©mie PrÃ©vost

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10850934/publications.pdf>

Version: 2024-02-01

56
papers

3,469
citations

196777

29
h-index

198040

52
g-index

74
all docs

74
docs citations

74
times ranked

5071
citing authors

#	ARTICLE	IF	CITATIONS
1	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Host and Microbe</i> , 2022, 30, 97-109.e5.	5.1	83
2	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. <i>Cell Reports</i> , 2022, 38, 110210.	2.9	96
3	Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4 ⁺ T Cell. <i>Journal of Virology</i> , 2022, 96, jvi0192921.	1.5	10
4	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. <i>Cell Reports</i> , 2022, 38, 110368.	2.9	82
5	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. <i>PLoS Pathogens</i> , 2022, 18, e1010183.	2.1	8
6	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. <i>Cell Reports</i> , 2022, 38, 110429.	2.9	50
7	SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells. <i>Viruses</i> , 2022, 14, 5.	1.5	16
8	High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples. <i>Transfusion</i> , 2021, 61, 1377-1382.	0.8	17
9	Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. <i>Cell Reports</i> , 2021, 34, 108790.	2.9	94
10	The great escape? SARS-CoV-2 variants evading neutralizing responses. <i>Cell Host and Microbe</i> , 2021, 29, 322-324.	5.1	78
11	Identification of SARS-CoV-2-specific immune alterations in acutely ill patients. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	24
12	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab220.	0.4	33
13	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. <i>Cell Reports Medicine</i> , 2021, 2, 100290.	3.3	145
14	SARS-CoV-2 seroprevalence among blood donors in Quebec, and analysis of symptoms associated with seropositivity: a nested case-control study. <i>Canadian Journal of Public Health</i> , 2021, 112, 576-586.	1.1	18
15	Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. <i>Cell Host and Microbe</i> , 2021, 29, 904-916.e6.	5.1	29
16	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses. <i>Cell Host and Microbe</i> , 2021, 29, 1137-1150.e6.	5.1	173
17	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2021, 95, e0079621.	1.5	6
18	Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells. <i>MBio</i> , 2021, 12, e0140521.	1.8	3

#	ARTICLE	IF	CITATIONS
19	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. <i>Immunity</i> , 2021, 54, 2143-2158.e15.	6.6	155
20	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. <i>Nature Medicine</i> , 2021, 27, 2012-2024.	15.2	206
21	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. <i>Journal of Biological Chemistry</i> , 2021, 297, 101151.	1.6	42
22	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. <i>Virology</i> , 2021, 563, 134-145.	1.1	74
23	A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells. <i>STAR Protocols</i> , 2021, 2, 100851.	0.5	28
24	HIV-1 Envelope Glycoproteins Proteolytic Cleavage Protects Infected Cells from ADCC Mediated by Plasma from Infected Individuals. <i>Viruses</i> , 2021, 13, 2236.	1.5	2
25	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629.	4.7	32
26	Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays. <i>Microbiology Spectrum</i> , 2021, 9, e0088621.	1.2	17
27	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. <i>MBio</i> , 2020, 11, .	1.8	186
28	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. <i>Viruses</i> , 2020, 12, 1104.	1.5	29
29	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. <i>Cell Reports Medicine</i> , 2020, 1, 100126.	3.3	200
30	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. <i>Cell Host and Microbe</i> , 2020, 28, 880-891.e8.	5.1	153
31	Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells. <i>Microorganisms</i> , 2020, 8, 710.	1.6	7
32	The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site. <i>MBio</i> , 2020, 11, .	1.8	37
33	Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. <i>Blood</i> , 2020, 136, 2588-2591.	0.6	127
34	A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	26
35	Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses. <i>MBio</i> , 2019, 10, .	1.8	16
36	Antibody-Induced Internalization of HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env. <i>Journal of Virology</i> , 2019, 93, .	1.5	32

#	ARTICLE	IF	CITATIONS
37	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
38	An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity. <i>Cell Host and Microbe</i> , 2019, 25, 578-587.e5.	5.1	93
39	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. <i>Immunity</i> , 2019, 50, 241-252.e6.	6.6	153
40	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. <i>Journal of Virology</i> , 2019, 93, .	1.5	44
41	Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. <i>Virology</i> , 2018, 515, 38-45.	1.1	40
42	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. <i>Journal of Virology</i> , 2018, 92, .	1.5	56
43	Impact of HIV-1 Envelope Conformation on ADCC Responses. <i>Trends in Microbiology</i> , 2018, 26, 253-265.	3.5	64
44	SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement. <i>Journal of Virology</i> , 2018, 92, .	1.5	24
45	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. <i>MBio</i> , 2018, 9, .	1.8	82
46	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. <i>Nature Communications</i> , 2018, 9, 2363.	5.8	46
47	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017, 91, .	1.5	52
48	Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	30
49	BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
50	Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. <i>Journal of Virology</i> , 2017, 91, .	1.5	53
51	Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
52	HIV-1 gp120 envelope glycoprotein determinants for cytokine burst in human monocytes. <i>PLoS ONE</i> , 2017, 12, e0174550.	1.1	15
53	A Highly Conserved gp120 Inner Domain Residue Modulates Env Conformation and Trimer Stability. <i>Journal of Virology</i> , 2016, 90, 8395-8409.	1.5	15
54	Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus. <i>Journal of Virology</i> , 2016, 90, 10065-10073.	1.5	6

#	ARTICLE	IF	CITATIONS
55	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. EBioMedicine, 2016, 12, 208-218.	2.7	65
56	A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. Journal of Virology, 2016, 90, 2127-2134.	1.5	69